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HIV positive women in Addis Ababa, Ethiopia:
a cross sectional survey
Hussen Mekonnen Asfaw* and Fikre Enquselassie GasheAbstract
Background: Prevention of unplanned pregnancies among people living with HIV is essential component of
“Global Plan” even in the context of expanded access to highly active antiretroviral therapy (HAART). The study
aimed to assess whether contraceptive use and method preference varied by the use of HAART among HIV positive
women in Addis Ababa, Ethiopia.
Methods: A cross sectional facility based survey was conducted from June to October, 2012 information was
gathered using interviewer administered questionnaire and document review was conducted to confirm HIV
status and clinical review. A sample of 1418 HIV positive women including 770 women receiving HAART and
648 HAART-naïve recruited randomly from different health institutions in Addis Ababa. Data were principally
analyzed using logistic regression.
Result: Overall, 71% women reported using contraception (75% among HAART users and 65% HAART naïve
women). Male condom and injectables are the most preferred contraceptive methods among both groups.
The odds of contraceptive use among HAART users was higher (AOR 1.60, 95% CI; 1.30-2.12) than HAART
naïve women. In addition to this, presence of partner (AOR 2.32, 95% CI 1.60-3.40), disclosure of HIV status to
husband (AOR 2.23; 95% CI 1.21-4.12), presence of living children: one (AOR 1.7; 95% CI 1.03-2.40), two (AOR
2.6; 95% CI 1.7-4.02) and three (AOR 3.3; 95% CI 1.90-5.60) respectively were found to be predictors of
contraceptive use among HIV positive women.
Conclusion: The contraceptive profile of women in the study area mainly dependent on male condom use,
this indicates the need to better integrate tailored counseling and contraceptive options with care and support
activities that targets HIV positive women. Moreover, emphasis should be given to dual contraceptive method use
along with their regular follow up irrespective of their HAART use.
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Sub-Saharan Africa is the region most severely affected
by HIV [1]. Women of productive age account for 58%
of the people living with HIV [2] and 53% of all adult
deaths [3]. In Ethiopia, more women (2.9%) than men
(1.9%) are living with HIV [4]. Most of these women are
particularly vulnerable to HIV due to complex burden
they have [5] including physiological, social vulnerability
and gender inequalities [3].* Correspondence: hussen_mk@yahoo.com
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article, unless otherwise stated.Furthermore, HIV positive women have risk of un-
planned pregnancies [6]. Worldwide, two in every five
pregnancies are unplanned [7]. Previous studies of 42 sub-
Saharan Africa countries, 10-65% of women reported that
their last pregnancy had been unplanned [8]. Similarly,
62% of women on ART from South African [9] and 59%
of HIV positive women from Kenya reported unplanned
pregnancy [10].
Prevention of unintended pregnancy among HIV posi-
tive women is the second element of prevention of mother
to child transmission of HIV (PMTCT) [11] which is an
important means to address the associated problems ofntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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to be cost effective [13], improves quality of life [14],
reduces maternal and child mortality [3,12,15-17] and
reduces number of positive infants by keeping their
mother alive [18].
Significant improvements have been demonstrated by
PMTCT in low and middle income countries [19]. The
percentage of pregnant women with HIV receiving anti-
retroviral therapy(ART) using PMTCT in sub Saharan
Africa increased to 50% [3]. However, PMTCT efforts to
date gave less emphasis to the contraceptives options [20].
Despite the potential contribution of family planning(FP)
to the prevention of HIV infection [12] and unintended
pregnancies [3], contraceptive use in sub-Saharan Africa
remains low [21]. The percentage of married women aged
15–49 using modern contraceptive methods ranges from
12% in Mozambique and 14% in Ethiopia to 27% in
Rwanda [4]. In addition, previous reports indicated that
twenty five percent of women with HIV worldwide and
one in four married women from sub-Saharan Africa has
unmet need for family planning [22].
Even in the context of expanded access to ART for
HIV-infected pregnant women, family planning still
needs to be strengthened to avoid unintended pregnan-
cies [23]. Existing evidence revealed that women living
with HIV including those taking ARVs can use almost
all contraceptive methods safely and effectively [15,16]
with variation in method preference [5,12,24-27].
Previous studies from different parts of Ethiopia re-
ported that of those who have ever used at least one
contraceptive method after HIV diagnosis, condom, in-
jectables and abstinence were reported to be the most
preferred methods [28-30]. However, information on in-
formed choice of contraceptive methods, reasons for se-
lection of methods and the influence of HAART on the
contraceptive use of women entering HIV care is scarce.
Ethiopia is the second populous country in Africa [31],
characterized by high fertility of 5.4% children per woman
[4], having more children is highly valued [32]. More-
over, majority of women deliver at home (usually without
skilled attendant) where complications of childbirth
cannot be addressed, including the risk of mother-to-
child transmission of HIV [31]; identification of factors
associated with contraceptive use and method preference
among HAART using women is an important issue to be
addressed.
Thus, given the importance of contraceptive use in
preventing unintended pregnancy, perinatal transmission
of HIV [3] and ART scale up in Ethiopia; it is worth to
assess contraceptive use and method preference of HIV
positive women. It is anticipated that this research will
update existing knowledge, inform policy makers and
programmers to support safer and healthier reproductive
options among HIV positive women in the study area.Methods
The study was conducted in health facilities of Addis
Ababa, Ethiopia. In the country, Antiretroviral treatment
began in 2003 and free ART was launched in 2005 [33].
Since then, a total of five public hospitals and twenty five
health centers have been offering ART [34]. About 124,983
people living with HIV were enrolled of whom 76,035 have
started and 54,667 are currently on ART in the city [4].
Amhara is the predominant ethnic group and Amharic is
commonly spoken language in the study area [35].
Study design and sampling procedures
A cross sectional survey was carried out at selected pub-
lic health facilities (hospitals & health center) of Addis
Ababa between June and October, 2012. Non-pregnant
women aged 18–49 years, reported having sexual rela-
tionship six months prior to the data collection period
were eligible to participate in this study.
Sample size was computed using two-proportion for-
mula with the assumption of proportion of contracep-
tive use among HIV positive women receiving HAART
and HAART naïve being 86% and 82%, respectively [12],
with a minimum detectable odds ratio of 2 at 5%
level of significance power of 90% with a design effect
of 2 and 5% addition for non-response rate a total
sample size of 1924. However, the number of women
who satisfy the eligibility criteria at the records of the
health facilities was 1418 (770 HAART users and 648
HAART- naïve).
Study participants were selected using multi-stage sam-
pling technique. Initially, five hospitals and seven health
centers were selected by lottery methods, and then the
total sample size was proportionally allocated to the se-
lected facilities according to the client load in each institu-
tion. Finally individual study subjects were selected using
a systematic random sampling technique from the records
of each selected facility.
Data collection
Data were collected using interviewer administered struc-
tured questionnaires adopted from previous similar study
[12]. The questionnaire has been translated in to the local
language (Amharic) by experts in both languages and
back translated to English by another person to ensure
consistency and accuracy. Data collectors were all female
nurses recruited based on their previous experience in
data collection, those who had previous training on ART
and/or HIV counseling and fluency of the local language.
Moreover, training was given for five consecutive days on
interview techniques, sampling and ethical issues, empha-
sizing the importance of safety of participants and inter-
viewers, minimization of under reporting and maintaining
confidentiality. A pre-test of the questionnaire was con-
ducted in selected ART units which were not included in
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supervised by the principal investigator.
Measurements
The primary outcome variable was self-reported contra-
ceptive use for the previous six months prior to the data col-
lection period. In this study contraceptive use was defined
the use of any method including injectables (Depot), im-
plants (implanol or jadelle), oral contraceptive pill (OCP),
intra uterine contraceptive device (lUCD), male/female
condom, diaphragm, permanent methods such as tubal
ligation and hysterectomy. Dual contraceptive method
was defined as use of primarily the male condom with
hormonal or other contraceptive methods like IUCD.
Consistent condom use was defined as the use of con-
doms always or frequently in all vaginal sexual relation-
ships with casual and/or steady partners. Women who
used condoms sometimes or rarely were regarded as in-
consistent condom users.
Independent variables in this study included were age,
education, employment, monthly household income,
sexual partnership status, HIV sero-status of partner/
husband, number of living children, HIV test of children,
disclosure of HIV status to partner/husband and discussion
with partner/husband or health workers about contracep-
tion. Medical record review was also conducted to confirm
HAART history and obtain clinical data including World
Health Organization stage of disease and CD4 cell count.
Antiretroviral therapy (ART) is treatment of people in-
fected with human immunodeficiency virus (HIV) using
anti-HIV drugs [36]. The standard treatment consists of a
combination of at least three drugs (often called “highly
active antiretroviral therapy” or HAART) that suppress
HIV replication [37]. Highly active anti retroviral therapy
(HAART) use defined as use of one of three antiretroviral
medications either Efaveranze (EFV) or Neverapin (NVP)
based [5,12,38] first line drugs or use of combination
drugs with protease inhibitors(PIs) backbone of second
line drugs [38]. We considered women to be HAART
users if they had been receiving HAART for at least one
month and HAART-naïve if they had never taken
HAART, prior to the data collection period.
Analysis
The pre coded responses were double entered in EPI
Info version 3.5.2 software, for checking its consistency
then was exported to SPSS for window version 20 for
statistical analysis. Uses, preference and reasons for se-
lection of contraceptive methods are presented using de-
scriptive statistics. Variables found to be significant at
bivariate level, (P < 0.05), were selected and included in to
multiple logistic regression models. Then multiple logistic
regression analyses were used to calculate Odds ratio with
95% confidence interval to estimate association and tocontrol the potential confounding variables. Strength
and direction of the association between contraceptive
use and potential socio-demographic, reproductive health
and clinical factors were presented using odds ratios rela-
tive to the reference category and 95% confidence levels.
Ethical considerations
The research was approved for scientific and ethical integ-
rity by the Institutional Review Board (IRB) of College of
Health Sciences, Addis Ababa University. Written permis-
sion was obtained from health bureau of the Addis Ababa
city government. Consent was obtained from medical di-
rectors and respective unit heads at each health institu-
tions. Verbal consent was also obtained from individual
clients. In order to make informed decision sufficient in-
formation was given to each participant. Confidentiality
was strictly maintained for each piece of information and
the interview was conducted in strict private place. At the
end of the interview general information, referral and fol-
low up linkages were made for those who need.
Results
Socio-demographic characteristics of study participants
Of the total 1418 women who participated in this study,
423 (29.8%) were in the age range of 30–34 years, with
mean (standard deviation) of 31.1(±5.5). The study par-
ticipants were predominantly Orthodox Christians 1109
(78.2%) and Amhara 849(59.9%) by religion and ethnicity,
respectively. Occupationally, 373 (26.3%) participants had
their own private business and 292(20.6%) were house-
wives. Concerning educational status of the participants,
538 (37.9%) have completed grade 1–8, 466(32.9) grade
9–12 and 133(9.4%) with higher education. Four hundred
nineteen (29.5) earn monthly income of less than 1000
Ethiopian birr and 390 (27.5%) women were with no
monthly income. Concerning marital status, about 62% of
the participants are currently married/cohabited and 242
(17.1%) were single (Table 1).
Reproductive and clinical characteristics of study
participants
About 55%(422/769) of HAART users and 45% (347/769)
HAART naïve women had recent CD4 counts of 350 cell/
mm3 and 42% (363/863) and 58% (500/863) HAART users
and HAART naïve, respectively were in WHO stage of dis-
ease I or II. About 70.3% (997/1418) of the study partici-
pants reported ever had sexual partner in their life time.
Of these women who had partners, 81.8% (816/997) re-
ported that their partners were tested for HIV, and 73.8%
(602/816) are positive for HIV. Of the total study partici-
pants, 463(32.7%) women reported having one child, 321
(22.6%) two children and 428(30.2%) no children. About
59% (507/859) and 41% (352/859) HAART users and
HAART naïve women, respectively, had disclosed HIV
Table 1 Socio-demographic characteristics of HIV positive women in Addis Ababa, Ethiopia (n = 1418)
Socio-demographic characteristics HAART users (n = 770) HAART Naïve (n = 648) Total
No (%) No (%) No (%)
Age (in years)
18-24 58 (7.5) 91 (14.0) 149 (10.5)
25-29 219 (28.4) 20 3(31.3) 422 (29.8)
30-34 245 (31.8) 178 (27.5) 423 (29.8)
35-39 186 (24.2) 122 (18.8) 308 (21.7)
40-49 62 (8.1) 54 (8.3) 116 (8.2)
Mean (SD) Age in years 31.6 (±5.2) 30.4 (±5.8) 31.1 (±5.5)
Ethnicity
Amhara 462 (60.0) 387 (59.7) 849 (59.9)
Oromo 167 (21.7) 147 (22.7) 314 (22.1)
Gurage 70 (9.1) 54 (8.3) 124 (8.7)
Tigrea 47 (6.1) 32 (4.9) 79 (5.6)
Others (Silte,gamo, welayta, yem, Sidama) 24 (3.1) 28 (4.3) 52 (3.7)
Religion
Orthodox Christian 604 (78.4) 505 (78.0) 1109 (78.2)
Muslim 84 (10.9) 76 (11.7) 160 (11.3)
Others (Protestant, catholic, Jubbah) 82 (10.6) 67 (10.3) 149 (10.5)
Marital status
Single 126 (16.4) 116 (17.9) 242 (17.1)
Married/cohabited 488 (63.4) 397 (61.3) 885 (62.4)
Widowed 81 (10.5) 55 (8.5) 136 (9.6)
Divorced 75 (9.7) 80 (12.3) 155 (10.9)
Educational status
illiterate 91 (11.8) 78 (12.0) 169 (11.9)
Informal education 50 (6.5) 62 (9.6) 112 (7.9)
Grade 1–8 completed 273 (35.5) 265 (40.9) 538 (37.9)
Grade 9–12 completed 290 (37.6) 176 (27.2) 466 (32.9)
above 12 grade 66 (8.6) 67 (10.3) 133 (9.4)
Occupation
unemployed 131 (17.0) 133 (20.5) 264 (18.6)
Housewife 166 (21.6) 126 (19.4) 292 (20.6)
Daily laborer 96 (12.5) 112 (17.3) 208 (14.7)
Merchant 40 (5.2) 36 (5.6) 76 (5.4)
CSW 18 (2.3) 13 (2.0) 31 (2.2)
Government worker 90 (11.7) 84 (30.6) 174 (12.3)
Private business 229 (29.7) 144 (22.2) 373 (26.3)
Monthly Income (in Birr)*
No Income 192 (24.9) 198 (30.6) 390 (27.5)
Birr below 500 217 (28.2) 144 (22.2) 361 (25.5)
Birr 500-1000 227 (29.5) 192 (29.6) 419 (29.5)
Birr 1001-3000 112 (14.5) 97 (15.0) 209 (14.7)
Birr above 300 22 (2.9) 17 (2.6) 39 (2.8)
*Birr = (1USD = 18.80 ETB).
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women reported they had open discussion with partner/
husband (Table 2).
Use and preference of contraceptive methods
Overall contraceptive use was 71% (75% (579/770) and
65% (422/648) among HAART users and 42% HAART-
naïve women, respectively). Four hundred five (28.8%)
reported did not use contraceptive methods six months
prior to the data collection period while contraceptive
status was not known for 9 (0.6%) women (Table 3). In
general male condom is the most preferred contracep-
tive method 45.7% (468/1001) followed by injectables
30.5% (306/1001) (Table 3).
Reasons given in choosing contraceptive methods
The primary reason given for contraceptive use was for
protection against STIs in 28% (281/1001) followed by
prevention of unwanted pregnancy in 21% (208/1001),
among women using any method. Other reasons men-
tioned were convenient to use 18% (180/1001), easy to
use 14% (138/1001), does not interfere with sexual activ-
ity 8% (82/1001), advise of health workers 5% (50/1001),
and the like (Figure 1).
Factors associated with contraceptive use
Using the logistic regression model, a number of socio-
demographic, HAART use, sexual history, disclosure be-
havior and clinical factors were identified as significant
predictors of the association of contraceptive use (Table 4).
The results showed that HAART use has influence
on women’s decision to use contraceptives compared to
HAART naïve women, the odds of contraceptive use
among HAART users was significantly higher, adjusted
for other potential confounders (AOR 1.60, 95% CI; 1.30
to 2.12). Similarly, women who had sexual partners cur-
rently were more likely to use contraceptives than women
with no partners (AOR 2.32, 95% CI 1.60 to 3.40). On the
other hand, married/cohabited (AOR 0.41, 95% CI 0.21 to
0.80) and widowed women (AOR 0.31, 95% CI 0.12 to
0.84) respectively, had less likely to use contraceptive
methods compared to that of single women.
Disclosure of HIV status, especially, with sexual part-
ner has significant association with contraceptive use,
women who disclosed their HIV status to partner were
about two times more likely to use contraceptive than
women who did not (AOR 2.23, 95% CI 1.21 to 4.12).
Furthermore, women who reported open discussion with
their partner/husband were about two times more likely
to use contraceptives than those who reported no dis-
cussion (AOR 2.0, 95% CI; 1.60 to 2.60).
Contraceptive use also increased by the number of liv-
ing children women have. The odds of contraceptive use
for women who have one child (AOR 1.7, 95% CI 1.03to 2.40), two children (AOR 2.6; 95% CI 1.7 to 4.02) and
three or more children (AOR 3.3, 95% CI 1.90 to 5.60),
respectively, were higher than women with no children.
Similarly, the odds of contraceptive use was higher for
women whose children are tested for HIV than women
who did not (AOR, 1.6; 95% CI; 1.01 to 2.40).
Discussion
The issue of contraceptive use and method preference
among women enrolled in HIV care and treatment pro-
grams in the study area has important implications for
the health of women and their infants. Overall the propor-
tion of contraceptive use was 71% irrespective of their
HAART use. Previous studies from Uganda and South
Africa reported higher than our finding 85% and 78%, re-
spectively [5,12]. On the other hand, our finding showed
higher proportion than previous findings from other de-
veloping countries, which reported between 28 and 53%
[39-42] and than earlier reports within the country re-
ported 43 to 54% [29,30,43]. The difference is associated
with study time and study subject differences.
The result is different from contraceptive use of the
general female population in Addis Ababa reported 63%
[44]. The most probable reason might be that HIV posi-
tive women have frequent contact with health care pro-
viders and demand for contraceptives might be higher
than the general population.
In the logistic model, we found that, adjusted for poten-
tial confounders, contraceptive use was significantly higher
among women receiving HAART than HAART naïve;
which was also reported by previous studies from Uganda
and South Africa [5,12]. This may be a reflection of the fact
that continual exposures to secondary prevention messages
along with ART might have impact on contraceptive use.
Even though, male condom is the most preferred method
by all study participants, it was higher among those receiv-
ing HAART compared to HAART naïve women (54 vs
37%, respectively).
While the use of dual contraceptive methods (condom
with other methods) is safe to prevent unintended preg-
nancy and HIV [25,45]. However, low proportion (14.7%)
of dual contraceptive method use was observed among
HAART users. This may reflect that the study population
is at risk of acquiring sexually transmitted infection in-
cluding drug resistant HIV virus.
Our findings has also showed that women with living
children have reported contraceptive use than those with
no children; the result was consistent with studies re-
ported from Uganda and South Africa [5,12]. This sug-
gests that the desire to have children among those with
no children is higher for obvious reasons and conse-
quently avoiding contraceptive use.
Furthermore, women who have open discussion with
partner or health care providers have better contraceptive
Table 2 Reproductive and clinical characteristics of HIV positive women in Addis Ababa, Ethiopia (n = 1418)
Reproductive and clinical history HAART users (n = 770) HAART naïves (n = 648) Total
No (%) No (%) No (%)
Nadir CD4 count
0-199 cells/mm3 466 (79.2) 97 (20.8) 563 (39.7)
200-349 cells/mm3 225 (45.9) 265 (54.1) 490 (34.6)
350+ cells/mm3 79 (21.6) 286 (78.4) 365 (25.7)
Current CD4 count
0-199 cells/mm3 125 (64.4) 69 (35.6) 194 (13.7)
200-349 cells/mm3 223 (49) 232 (51) 455 (32.1)
350+ cells/mm3 422 (55) 347 (45) 769 (54.2)
WHO stage of Disease
Stage I/II 363 (42) 500 (58) 863 (60.9)
Stage III/IV 407 (73.3) 148 (26.7) 555 (39.1)
Presence of partner
Yes 560 (56.2) 437 (43.8) 997 (70.3)
No 210 (50) 211 (50) 421 (29.7)
Partner tested (n = 997)
Yes 479 (59) 337 (41) 816 (81.8)
No 47 (48) 50 (52) 97 (9.7)
I do not know 34 (40) 50 (60) 84 (8.4)
Test result of current partner (n = 816)
Positive 347 (58) 255 (42) 602 (73.8)
Negative 119 (60) 73 (40) 199 (24.4)
I do not know 13 (87) 2 (13) 15 (1.8)
Child tested (n = 990)
Yes 377 (58) 273 (42) 650 (65.6)
No 175 (51) 165 (40) 340 (34.3)
Disclose HIV status to anybody
Yes 722 (56.3) 558 (43.7) 1280 (90.3)
No 48 (34.7) 90 (65.3) 138 (9.7)
Disclosed HIV status to husband (n = 997)
Yes 507 (59) 352 (41) 859 (86.2)
No 53 (38.4) 85 (61.6) 138 (13.8)
Number of living children
0 218 (51) 210 (40) 428 (30.2)
1 260 (51) 203 (49) 463 (32.7)
2 180 (56) 141 (44) 321 (22.6)
3+ 112 (54.3) 94 (45.7) 206 (14.5)
Discussed with husband/Partner (n = 997)
Yes 384 (57.8) 280 (42.2) 664 (66.6)
No 176 (52.8) 157 (47.2) 333 (33.4)
Discussed with HCWs*
Yes 553 (54.7) 457 (45.3) 1010 (71.2)
No 217 (52.8) 191 (47.2) 408 (28.8)
*HCWs: health care workers.
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Table 3 Use and preference of contraceptive methods among HIV positive women in Addis Ababa, Ethiopia
Type of contraceptives HAART users (n = 770) HAART Naives (n = 648) Total
No (%) No (%) No (%)
Contraceptive use
Yes 579 (75.2) 422 (65.1) 1001 (70.6)
No 186 (24.2) 222 (54.3) 408 (28.8)
Not known 5 (0.6) 4 (0.6) 9 (0.6)
Method preference
Injectables (Depot) 146 (25.2) 160 (37.9) 306 (30.5)
Oral contraceptive pills (OCP) of available type 55 (9.4) 46 (11) 101 (10.0)
Intra uterine contraceptive device (IUCD) 16 (2.7) 12 (2.8) 28 (2.8)
Implant (Jaddelle or Implanon) 48 (8.2) 45 (10.5) 93 (9.2)
Consistent male condom use 310 (53.5) 158 (37.4) 468 (46.7)
Female condom 4 (0.7) 1 (0.2) 5 (0.5)
Categories of contraceptives methods
Dual contraceptive methods (condom and hormonal methods) 98 (14.7) 114 (21.6) 212 (18)
Barrier Methods (male or female condom) 317 (47.5) 161 (30.6) 478 (40)
Hormonal methods (OCPs, Implant and Depot) 249 (37.5) 251 (39.9) 500 (42)
N.B. a woman may have reported the use of ≥ 1 method value will not be added to 100%.
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ure of HIV status to a partner may be important to get
support from family and discussion can clarify uncertain-
ties about contraceptives and possibly to strengthen confi-
dence of women. Besides women who knew the HIV
status of their children reported contraceptive use than
their counter parts, this could be related to women who
tested their children have better exposure and more con-
cerned on the prevention of unintended pregnancies.
Our study has several limitations; due to cross-
sectional nature we are unable to make definitive con-
clusions on cause and effect relation. The association
could only be discussed in terms of plausibility. Further-
more, social desirability and stigma may have biasedFigure 1 Reasons given in choosing methods of prevention among Hrespondents’ answers and may not be generalizable to
HIV-positive female population in the care.
As to the strengths of this study, the respondents have
been selected by random sampling technique with rela-
tively large sample size. Again, the team already adopted
instrument conducted in other developing countries
[12]. Precautions have been taken in selection of experi-
enced data collectors.
Conclusion
The study identified that HIV positive women in general
and women receiving HAART in particular are more
likely to use contraceptives with preference of male con-
dom. Its protection against STIs followed by prevention ofIV positive women in Addis Ababa, Ethiopia.
Table 4 Adjusted analyses of variables associated with contraceptive use among women in Addis Ababa, Ethiopia
Variables Contraceptive use Adjusted odds ratio
AOR (95% CI)
Yes No
No. (%) No. (%)
HAART use
No 422 (42.2) 226 (55.4) 1.00
Yes 579 (57.8) 191 (45.6) 1.6 (1.30-2.12)**
Presence of partner
No 236 (26.6) 185 (44.4) 1.00
Yes 765 (76.4)) 232 (55.6) 2.32 (1.60-3.40)**
Disclosed HIV status to husband
No 87 (11.4) 51 (22.1) 1.00
Yes 679 (88.6) 180 (77.9) 2.23 (1.21-4.12)**
Discussed with husband
No 240 (31.3) 99 (42.9) 1.00
Yes 526 (68.7) 132 (57.1) 2.0 (1.60-2.60)**
Discussed with HWs
No 242 (24.9) 166 (39.8) 1.00
Yes 759 (75.1) 251 (60.2) 1.60 (1.20-2.03)**
Number of living Children
0 275 (27.5) 153 (36.7) 1.00
1 329 (32.9) 134 (32.1) 1.7 (1.03-2.40)**
2 241 (24.1) 80 (19.2) 2.6 (1.7-4.02)**
3+ 156 (15.6) 50 (12.0) 3.3 (1.90-5.60)**
Marital status
Single 168 (16.8) 74 (17.7) 1.00
Married/cohabited 673 (67.2) 212 (50.8) 0.41 (0.21-0.80)*
Widowed 73 (7.3) 63 (15.1) 0.31 (0.12-0.84)*
Divorced 87 (8.7) 68 (16.3) 0.80 (0.30-2.30)
Child tested for HIV
No 236 (32.5) 104 (39.3) 1.00
Yes 490 (67.4) 160 (60.6) 1.60 (1.10-2.40)*
*P value < 0.05 **P-value < 0.001.
Adjusted for age, education and other SES.
Asfaw and Gashe BMC Public Health 2014, 14:566 Page 8 of 10
http://www.biomedcentral.com/1471-2458/14/566unwanted pregnancy and convenient to use were among
the reasons mentioned for selection of the contraceptive
methods. Furthermore, having one or more living chil-
dren, disclosure of HIV status to sexual partner, open dis-
cussion with partner or health care workers found to be
predictors of contraceptive use in the study area. Low pro-
portion of dual contraceptive method use was observed
among HAART users. This may reflect that the study
population is at risk of acquiring sexually transmitted in-
fection including drug resistant HIV virus.
The contraceptive profile of women in the study area
mainly dependent on male condom use, this indicates
the need to better integrate tailored counseling and
contraceptive options with care and support activities
that targets HIV positive women. Moreover, emphasisshould be given to dual contraceptive method use along
with their regular follow up irrespective of their HAART
use.
Lastly extensive and longitudinal study is needed to
validate current findings so as to inform for policy
makers to establish better sexual and reproductive health
services for positive women to have planed and safe fer-
tility goal.
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